To test the ability of these DCs to cross-present captured tumor Ag to CD8+ T cells, we generated CRISPR gene-edited β2m−/− GFP+ A20 cells, which are unable to directly present GFP on MHC I. Splenocytes from untreated or Flt3L-treated mice were co-cultured with NDV-preinfected β2m−/− GFP+A20 cells; JEDI T cells were then added to the co-cultures and their activation assessed (Fig. 2g, left panel). This evidence concerns the gene FLT3LG and neoplasm.